About TCR2 Therapeutics
TCR2 Therapeutics, Inc. is an immunotherapy company, which is developing novel T cell therapies for patients suffering from cancer. The Company’s T cell receptor (TCR) Fusion Construct T cells (TRuC-T cells) specifically recognize and kill cancer cells by harnessing the entire T cell receptor (TCR) signaling complex. The Company has demonstrated anti-tumor activity of TRuC-T cells in preclinical models across various tumor targets. The Company has also developed combinations of TRuC variants with elements designed to sustain the immunotherapeutic response and counteract the immunosuppressive tumor microenvironment. Its platform is highlighted with multiple programs of product candidate, which include TC-210, TC-220, TC-410, TC-110 and TC-310.